

# Appendix 3B

## New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 1/7/96. Origin: Appendix 5. Amended 1/7/98, 1/9/99, 1/7/2000, 30/9/2001, 11/3/2002, 1/1/2003, 24/10/2005.

<b>Name of entity</b>	<b>Poseidon Nickel Limited</b>
<b>ACN</b>	<b>060 525 206</b>

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

- |   |  |  |
|---|--|--|
| 1 | +Class of +securities issued or to be issued   | Unlisted Performance Rights  |
| 2 | Number of +securities issued or to be issued (if known) or maximum number which may be issued  | 2,985,214  |
| 3 | Principal terms of the +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)   | <p>Each Right converts to one (1) fully paid Ordinary Share and are immediately exercisable.</p> <p>These Performance Rights are not subject to performance hurdles or forfeiture conditions.</p> <p>The Rights have been issued pursuant to Shareholder approval received at the 2016 Annual General Meeting held on 12 October 2016.</p> |
| 4 | <p>Do the +securities rank equally in all respects from the date of allotment with an existing +class of quoted +securities?</p> <p>If the additional securities do not rank equally, please state:</p> <ul style="list-style-type: none"> <li>• the date from which they do</li> <li>• the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>• the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul> | <p>The Unlisted Performance Rights rank equally with the existing unlisted class of Performance Rights.</p> <p>Upon vesting of the Rights and conversion to fully paid Ordinary Shares, the Issued Shares will rank equally in all respects with an existing class of quoted Securities.</p>   |

5	Issue price or consideration	<p><u>1,677,768 Performance Rights</u> Deemed issue price of \$0.0435 being the VWAP for the March 2017 quarter</p> <p><u>1,307,446 Performance Rights</u> Deemed issue prices being the VWAP for the months of January to March 2017 (\$0.0427, \$0.0463 and \$0.0392)</p>
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	<p><u>1,677,768 Unlisted Performance Rights</u> Issued under the terms of the Director Fees Performance Rights Plan in satisfaction of March 2017 quarter Director Fees as approved by Shareholders on 12 October 2016.</p> <p><u>1,307,446 Unlisted Performance Rights</u> Issue of Performance Rights under the Director Fees Performance Rights Plan to Mr Christopher Indermaur in satisfaction of Fees for additional part time duties in the absence of a CEO for March 2017 quarter as approved by Shareholders on 12 October 2016.</p>
6a	Is the entity an +eligible entity that has obtained security holder approval under rule 7.1A?  If Yes, complete sections 6b – 6h <i>in relation to the +securities the subject of this Appendix 3B</i> , and comply with section 6i	Yes
6b	The date the security holder resolution under rule 7.1A was passed	At the 12 October 2016 Annual General Meeting
6c	Number of +securities issued without security holder approval under rule 7.1	Nil
6d	Number of +securities issued with security holder approval under rule 7.1A	Nil
6e	Number of +securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	2,985,214 Unlisted Performance Rights (Approved at 12 October 2016 Annual General Meeting)
6f	Number of securities issued under an exception in rule 7.2	Nil
6g	If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.	Not Applicable
6h	If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A

6i	Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements	<u>Remaining Issue Capacity under rule 7.1</u> 62,761,887  <u>Remaining Issue Capacity under rule 7.1A</u> 82,996,722												
7	Issue dates	07 April 2017												
8	Number and +class of all +securities quoted on ASX (including the securities in clause 2 if applicable)	<table border="1"> <thead> <tr> <th>Number</th> <th>+Class</th> </tr> </thead> <tbody> <tr> <td><b>891,700,415</b></td> <td>Ordinary fully paid Shares</td> </tr> </tbody> </table>	Number	+Class	<b>891,700,415</b>	Ordinary fully paid Shares								
Number	+Class													
<b>891,700,415</b>	Ordinary fully paid Shares													
9	Number and +class of all +securities not quoted on ASX (including the securities in section 2 if applicable)	<table border="1"> <tbody> <tr> <td>277,421,093</td> <td>30 September 2020 USD\$17.5 Unsecured Note convertible at \$0.09</td> </tr> <tr> <td>12,396,708</td> <td>Unlisted Director Performance Rights</td> </tr> <tr> <td>293,011</td> <td>16 December 2022 Short Term Incentive Rights</td> </tr> <tr> <td>2,026,759</td> <td>16 December 2022 Long Term Incentive Rights</td> </tr> <tr> <td>5,978,776</td> <td>21 October 2023 Short Term Incentive Rights</td> </tr> <tr> <td>5,635,245</td> <td>21 October 2023 Long Term Incentive Rights</td> </tr> </tbody> </table>	277,421,093	30 September 2020 USD\$17.5 Unsecured Note convertible at \$0.09	12,396,708	Unlisted Director Performance Rights	293,011	16 December 2022 Short Term Incentive Rights	2,026,759	16 December 2022 Long Term Incentive Rights	5,978,776	21 October 2023 Short Term Incentive Rights	5,635,245	21 October 2023 Long Term Incentive Rights
277,421,093	30 September 2020 USD\$17.5 Unsecured Note convertible at \$0.09													
12,396,708	Unlisted Director Performance Rights													
293,011	16 December 2022 Short Term Incentive Rights													
2,026,759	16 December 2022 Long Term Incentive Rights													
5,978,776	21 October 2023 Short Term Incentive Rights													
5,635,245	21 October 2023 Long Term Incentive Rights													
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	Not Applicable												

## Part 2 - Bonus issue or pro rata issue

Questions 11 to 33 are not applicable

## Part 3 - Quotation of securities

*You need only complete this section if you are applying for quotation of securities*

34 Type of securities  
(tick one)

(a)  Securities described in Part 1

(b)  All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

Questions 35 to 42 not applicable

### Quotation agreement

1 +Quotation of our additional +securities is in ASX's absolute discretion. ASX may quote the +securities on any conditions it decides.

2 We warrant the following to ASX.


- The issue of the +securities to be quoted complies with the law and is not for an illegal purpose.
- There is no reason why those +securities should not be granted +quotation.
- An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any +securities to be quoted and that no-one has any right to return any +securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the +securities be quoted.
- If we are a trust, we warrant that no person has the right to return the +securities to be quoted under section 1019B of the Corporations Act at the time that we request that the +securities be quoted.

3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.

4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before +quotation of the +securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.



Sign here:

Date: 07 April 2017

Print name: **Gareth Jones**  
**Company Secretary**

# Appendix 3B – Annexure 1

## Calculation of placement capacity under rule 7.1 and rule 7.1A for <sup>+</sup>eligible entities

Introduced 01/08/12

### Part 1

<b>Rule 7.1 – Issues exceeding 15% of capital</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<i>Insert</i> number of fully paid ordinary securities on issue 12 months before date of issue or agreement to issue	706,902,413
<p><b>Add</b> the following:</p> <ul style="list-style-type: none"> <li>• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2</li> <li>• Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> <li>• Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>Include only ordinary securities here – other classes of equity securities cannot be added</i></li> <li>• <i>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	<p>1,056,084 Shares issued 13/04/16 532,544 Shares issued 12/07/16 21,015 Shares issued 09/08/16 246,657 Shares issued 20/10/16</p> <p><i>Approval as at January 2016 GM</i> 25,108,845 Shares issued on 09/10/15</p> <p><i>Approval as at October 2016 AGM</i> 11,739,812 Shares issued on 05/01/16 16,200,000 Shares issued on 08/01/16 3,605,769 Shares issued on 15/01/16 3,832,926 Shares issued on 27/01/16 721,154 Shares issued on 24/02/16 20,000,000 Shares issued on 15/03/16 15,000,000 Shares issued on 09/06/16 10,000,000 Shares issued on 05/07/16 15,000,000 Shares issued on 09/08/16</p>
<b>Subtract</b> the number of fully paid ordinary securities cancelled during that 12 month period	N/A
<b>“A”</b>	829,967,222
<b>Step 2: Calculate 15% of “A”</b>	
<b>“B”</b>	0.15  <i>[Note: this value cannot be changed]</i>
<b>Multiply</b> “A” by 0.15	<b>124,495,083</b>

<b>Step 3: Calculate “C”, the amount of placement capacity under rule 7.1 that has already been used</b>	
<p><b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:</p> <ul style="list-style-type: none"> <li>• Under an exception in rule 7.2</li> <li>• Under rule 7.1A</li> <li>• With security holder approval under rule 7.1 or rule 7.4</li> </ul> <p><i>Note:</i></p> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities, unless specifically excluded – not just ordinary securities</i></li> <li>• <i>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	<p>61,733,196</p> <p>-</p> <p>-</p> <p>-</p>
<b>“C”</b>	<b>61,733,196</b>

<b>Step 4: Subtract “C” from [“A” x “B”] to calculate remaining placement capacity under rule 7.1</b>	
<p>“A” x 0.15</p> <p><i>Note: number must be same as shown in Step 2</i></p>	<p>124,495,083</p>
<p><b>Subtract “C”</b></p> <p><i>Note: number must be same as shown in Step 3</i></p>	<p>61,733,196</p>
<p><b>Total</b> [“A” x 0.15] – “C”</p>	<p><b>62,761,887</b></p> <p><i>[Note: this is the remaining placement capacity under rule 7.1]</i></p>

## Part 2

<b>Rule 7.1A – Additional placement capacity for eligible entities</b>	
<b>Step 1: Calculate “A”, the base figure from which the placement capacity is calculated</b>	
<b>“A”</b>  <i>Note: number must be same as shown in Step 1 of Part 1</i>	829,967,222
<b>Step 2: Calculate 10% of “A”</b>	
<b>“D”</b>	0.10  <i>Note: this value cannot be changed</i>
<b>Multiply “A” by 0.10</b>	<b>82,996,722</b>
<b>Step 3: Calculate “E”, the amount of placement capacity under rule 7.1A that has already been used</b>	
<b>Insert</b> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  <i>Notes:</i> <ul style="list-style-type: none"> <li>• <i>This applies to equity securities – not just ordinary securities</i></li> <li>• <i>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</i></li> <li>• <i>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</i></li> <li>• <i>It may be useful to set out issues of securities on different dates as separate line items</i></li> </ul>	-
<b>“E”</b>	-

<b>Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A</b>	
"A" x 0.10  <i>Note: number must be same as shown in Step 2</i>	82,996,722
<b>Subtract "E"</b>  <i>Note: number must be same as shown in Step 3</i>	-
<b>Total</b> ["A" x 0.10] – "E"	<b>82,996,722</b>  <i>Note: this is the remaining placement capacity under rule 7.1A</i>